WebMDreports a new drug called quilizumab has the potential to treat mild asthma and allergy symptoms. The drug, targets blood cells that produce immunoglobulin type E (IgE), a protein that causes allergic reactions. In an initial study, the drug reduced total levels of IgE in patients suffering from mild asthma or allergic reactions. The levels of IgE were kept low for a month on the drug. Results also show that production of IgE was not only reduced but stopped in some cases. In early stages of testing, the drug only seems to be working with mild asthma and not with moderate to severe cases. Quilizumab is aiming to replace its rival, omalizumab, which requires one to three injections every two to four weeks. Quilizumab, on the other hand, only requires one inhalation approximately every three months.
WebMD News from HealthDay
By Dennis Thompson
WEDNESDAY, July 2, 2014 (HealthDay News) — A new inhaled medication has the potential to treat mildasthma andallergies by interrupting the production of an immune system protein that triggers allergic reactions, a new study reports.
The drug, quilizumab, targets the blood cells that produce a protein called immunoglobulin type E (IgE), that serves a key role in allergies.
Quilizumab lowered total levels of IgE in theblood of people with allergies and mild asthma, and kept them low for a month, researchers report in the July 2 issue of the journal Science Translational Medicine.